Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 7/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1312420 | 0.88 | DRD2 (0.54) | DRD2ALDH1A1KDM4ETSHR | |
| SCHEMBL1312318 | 0.83 | DRD2 (0.49) | DRD2ALDH1A1KDM4ETSHR | |
| SCHEMBL1313273 | 0.82 | CHRM4 (0.39) | L3MBTL1HTTALDH1A1TSHR | |
| SCHEMBL1313249 | 0.80 | TSHR (0.33) | L3MBTL1HTTKMT2ADRD2ALDH1A1 | |
| SCHEMBL12120000 | 0.80 | PDGFRB (0.61) | HTTKMT2AMEN1DRD2 | |
| SCHEMBL1312919 | 0.77 | DRD2 (0.39) | L3MBTL1DRD2ALDH1A1KDM4ETSHR | |
| SCHEMBL1313254 | 0.72 | L3MBTL1 (0.47) | L3MBTL1HTTKMT2AMEN1DRD2 | |
| SCHEMBL1312312 | 0.71 | TSHR (0.38) | L3MBTL1DRD2ALDH1A1KDM4ETSHR | |
| SCHEMBL14020493 | 0.71 | L3MBTL1 (0.69) | L3MBTL1HTTKMT2AMEN1DRD2 | |
| SCHEMBL1313786 | 0.70 | ACKR3 (0.44) | L3MBTL1HTTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2292613-B1 | DIHYDROINDOLINONE DERIVATIVES | SHANGHAI INST PHARM INDUSTRY (CN) | 2015-09-30 | — | — | EP | disclosed |
| US-8829039-B2 | Dihydroindolinone derivatives | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2014-09-09 | — | — | US | disclosed |
| US-20110275671-A1 | DIHYDROINDOLINONE DERIVATIVES | Shanghai Institute of Pharmaceutical Indusrty (CN) | 2011-11-10 | — | — | US | disclosed |
| EP-2292613-A1 | DIHYDROINDOLINONE DERIVATIVES | Shanghai Institute of Pharmaceutical Industry (CN) | 2011-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275671-A1 | DIHYDROINDOLINONE DERIVATIVES | LCK, CDK5, ABL1 | L3MBTL1 4756/4885HTT 2891/4885KMT2A 2518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.